The contribution of unrecognized factors to the diabetes epidemic

Bergman, Michael; Jagannathan, Ram; Sesti, Giorgio

doi:10.1002/dmrr.3315

Cited by 3 publications

(2 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although there is a need for a formal technical health assessment, simulation of benefits from the 1-h PG as a classification tool in the Finnish population demonstrated improved quality of life, increased life expectancy and considerable cost savings. Alyass et al therefore concluded that the 1-h PG could have benefit in Finland as well as globally [70,104].…”

Section: Early Biomarker Of Dysglycemiamentioning

confidence: 99%

Review of methods for detecting glycemic disorders

Bergman

Abdul‐Ghani

Manco

et al. 2020

Diabetes Research and Clinical Practice

Self Cite

123

101

View full text Add to dashboard Cite

Highlights A 1-hour plasma glucose (1-h PG) threshold >155 mg/dl (8.6 mmol/L) during an oral glucose tolerance test (OGTT) may be a suitable biomarker for identifying normal glucose tolerant (NGT) individuals at risk for future type 2 diabetes (T2D). A one-hour, non-fasting, 50g Glucose Challenge Test (GCT) performed during a routine health care visit has potential for practical screening of glucose disorders. The shape of the glucose curve reflects the cumulative effect of insulin sensitivity and response on glucose concentrations with prospective studies warranted to evaluate its prognostic utility. The continuous glucose monitor (CGM) has facilitated insight into the pathophysiology of prediabetes and phenotypes of T2D and holds promise for detecting glycemic disorders. Metabolomic profiling including amino acids, lipids, carbohydrates and other metabolites may be useful for early diagnosis of glycemic disorders. Non-classical markers for assessing glycemic disorders including fructosamine, glycated albumin, and 1,5-anhydroglucitol that evaluate shorter periods of glucose exposure than HbA1c have potential use as adjunctive tools.

show abstract

Section: Early Biomarker Of Dysglycemiamentioning

confidence: 99%

Review of methods for detecting glycemic disorders

Bergman

Abdul‐Ghani

Manco

et al. 2020

Diabetes Research and Clinical Practice

Self Cite

123

101

View full text Add to dashboard Cite

show abstract

“…Noteworthy, such rate is similar to what observed with a multidrug pharmacologic strategy 20 . However, implementing such lifestyle interventions in clinical practice still remains challenging, likely due inadequate referral for lifestyle counselling and suboptimal training and education of healthcare professionals 21 . Those limiting factors may also explain the slight progression to overt diabetes observed in some patient (from 0% to 3.6%) Alongside, other unrecognized factors should be considered in individual with prediabetes.…”

Section: Discussionmentioning

confidence: 58%

Serum osteopontin predicts glycaemic profile improvement in metabolic syndrome: A pilot study

Caserza

Casula

Elia

et al. 2020

Eur J Clin Investigation

View full text Add to dashboard Cite

Prediabetes is often observed in patients with Metabolic Syndrome (MetS) and might be associated with metabolic and inflammatory alterations. Here, we investigated whether the inflammatory molecule osteopontin (OPN) might have a prognostic impact in a cohort of MetS patients (n = 85) with baseline normal glycaemia or impaired fasting glucose (IFG) over one year of recommended pharmacological treatments and Mediterranean diet. Patients were then followed up for 12 months with intermediate evaluation after 6 months. At all time points, anthropometric and clinical data were recorded, alongside with haematological and biochemical profiles, including serum concentrations of OPN. As expected, Mediterranean diet improves glycaemic profile in patients with IFG. Baseline serum OPN failed to be associated with baseline anthropometric or biochemical variables. At baseline, higher levels of OPN were shown in patients with IFG as compared to normal glycaemia. Two distinct subgroups of patients in whom OPN decreased or remained stable/increased at follow‐up were identified. When higher serum OPN levels were observed at baseline, greater reduction was observed at 1‐year follow‐up. Reduction in circulating OPN levels was associated with metabolic improvement in terms of blood pressure, LDL‐c, HDL‐c, and glycaemia. At both univariate and adjusted logistic regression analyses, serum OPN emerged as an independent predictor of glycaemic profile improvement at 1‐year follow‐up (adjOR 1.05 [1.00‐1.10]; P = .041). In conclusion, pharmacological and dietetic interventions improved glycaemic profile in patients with MetS. In particular, glycaemic improvement was demonstrated in patients who also reduce circulating OPN levels. Higher OPN levels at baseline predict normalization of glycaemic profile.

show abstract

The clinical effectiveness and safety of alprostadil combined with alpha lipoic acid in the treatment of diabetic peripheral neuropathy

Guan¹,

Cao²,

Zhang³

et al. 2020

Medicine

View full text Add to dashboard Cite

Background: The pathogenesis of diabetic peripheral neuropathy is more complex and it is not yet clear, but studies have shown that microangiopathy and oxidative stress responses are closely related to their pathogenesis. At present, the treatment of improving microcirculation and antioxidant stress is mainly used in clinical. Alprostadil is a commonly used vasodilator, and alpha lipoic acid is an antioxidant, which can effectively reduce oxidative stress responses and delay the progression of diabetes mellitus and its complications. However, there is a lack of evidence-based medical evidence for alprostadil combined with alpha lipoic acid in the treatment of diabetic peripheral neuropathy, and this article aims to understand the clinical effectiveness and safety of alprostadil combined with alpha lipoic acid in the treatment of diabetic peripheral neuropath by a meta-analysis of published randomized controlled trials. Methods: In this study, we obtain the relevant literature by retrieving 8 electronic databases, including PubMed, EMBASE, Web of Science, the Cochrane Library, CBM, CNKI, VIP, and WanFang Database. Retrieving a randomized controlled study of alprostadil combined with alpha lipoic acid in the treatment of diabetic peripheral neuropath, while the language of the literature is restricted and it only includes Chinese and English literature. For the publication of literature, the time is from the beginning of the database to August 31, 2020. In the English database, using the retrieval method of subject word combined free word. The two researchers read the titles and abstracts of all the literature independently based on the inclusion and exclusion criteria. If it cannot be determined whether the literature is included by reading the title and abstract, then download and read the full text of the literature. If there is a dispute between the two researchers about the literature, so it should discuss the dispute with the third researcher in order to reach a conclusion. Using the bias risk assessment tool of randomized controlled trials in Cochrane systematic review to evaluate the bias risk of the included literature; Using RevMan 5.3 software to conduct statistical analysis; Using funnel plot analysis to analyze the situation of literature publication bias. Results: This study will provide a high-quality evidence on the effects of hydrolyzed protein formula milk on gastrointestinal diseases and physical development of premature infants. Conclusion: This study will draw reliable evidence-based medical evidence for alprostadil combined with Alpha lipoic acid in the treatment of diabetic peripheral neuropathy, thus providing help for the clinical treatment of diabetic peripheral neuropathy. Registration number: Open Science Framework (OSF), registration number: DOI 10.17605/OSF.IO/7S46G.

show abstract

The contribution of unrecognized factors to the diabetes epidemic

Cited by 3 publications

References 24 publications

Review of methods for detecting glycemic disorders

Review of methods for detecting glycemic disorders

Serum osteopontin predicts glycaemic profile improvement in metabolic syndrome: A pilot study

The clinical effectiveness and safety of alprostadil combined with alpha lipoic acid in the treatment of diabetic peripheral neuropathy

Contact Info

Product

Resources

About